fosinopril / Generic mfg. - LARVOL DELTA

Impact of antihypertensive treatment on cardiovascular event reduction in patients with asymptomatic carotid artery stenosis: a systematic review and meta-analysis. (PubMed, Pan Afr Med J) - "The results reported that enalapril and fosinopril demonstrated dual benefits in blood pressure (BP) reduction and vascular remodeling, though meta-analysis showed statistically insignificant improvements in regional cerebral blood flow (CI: -0.84, 6.08, P = 0.14, I2= 94%). Similarly, isradipine, lacidipine, and amlodipine improved carotid hemodynamics and cerebral perfusion, with meta-analysis favoring calcium channel blocker intervention for blood pressure management (CI: -3.25 to 7.64, P = 0.43)...Moreover, beta-blockers showed specific benefits, with metoprolol improving plaque echogenicity (57.3 ± 16.8 vs. 51.8 ± 20.0, p = 0.006) and reducing cardiovascular events (17% vs. 37% placebo, p = 0.011), while labetalol effectively managed post-endarterectomy hypertension. In conclusion, antihypertensive treatments showed varying effectiveness in cardiovascular event reduction and improvements in vessel measures."

Clinical • Journal • Retrospective data • Review • Atherosclerosis • Cardiovascular • Hypertension

Fosinopril mediates antitumor efficacy by inducing GSDME-dependent pyroptosis in NSCLC. (PubMed, Cell Death Discov) - "This study provides the first evidence that fosinopril inhibits NSCLC via GSDME-dependent pyroptosis, triggered by ROS-induced mitochondrial dysfunction and caspase activation. Further investigation into the detailed mechanisms of fosinopril's anti-NSCLC activity is warranted."

Journal • Cardiovascular • Hepatocellular Cancer • Hypertension • Lung Cancer • Metabolic Disorders • Non Small Cell Lung Cancer • Oncology • Solid Tumor • CASP3 • CASP9 • GSDME

Amlodipine-Associated Angioedema: An Integrated Pharmacovigilance Assessment Using Disproportionality and Interaction Analysis and Case Reviews. (PubMed, J Clin Med) - "Significant safety signals were detected for amlodipine alone and in combination with aliskiren, specific ACE inhibitors (quinapril, benazepril, trandolapril, fosinopril, perindopril), and certain ARBs (candesartan, losartan). While these results should not discourage appropriate clinical use, they emphasize the importance of monitoring for angioedema, particularly during therapy initiation. The findings from this study need to be validated in prospective studies for further elucidation of the underlying mechanisms."

Adverse events • Journal • Cardiovascular • Hypertension

Effect of intestinal microbiota on adaptation to overcrowding stress in grouper (Epinephelus fuscoguttatus♀×E. lanceolatus♂). (PubMed, Fish Shellfish Immunol) - "The selected four associated metabolites (including creatine, fosinopril, 4-aminobutyric acid, and guanidinopropanoic acid) were validated to significantly reduce the expression of cellular inflammatory factors using the self-established grouper head kidney (HK) cell line. In conclusion, density pressure in the early culture period could affect the stability of the intestinal microbial environment of grouper. As aquaculture time increases, the intestinal microbial community of grouper drives the body's anti-inflammatory response and enhanced its adaptation to density pressure by regulating own structure and secretion of metabolites."

Journal • Inflammation • Inflammatory Bowel Disease • CXCL8 • IL1B • IL6 • TNFA

Fosinopril inhibits Ang II-induced VSMC proliferation, phenotype transformation, migration, and oxidative stress through the TGF-β1/Smad signaling pathway. (PubMed, Open Life Sci) - "Finally, FOS mitigates Ang II-induced VSMC proliferation, phenotypic transformation, migration, and oxidative stress by inhibiting the TGF-β1/Smad signaling pathway. In conclusion, these results suggest that FOS could be effective in managing vascular diseases, including hypertension."

Journal • Cardiovascular • Hypertension • MMP2 • MMP9 • NOX4 • SMAD2 • TGFB1

Effect of calf separation on gut microbiome and fecal metabolome of mother in the captive Yangtze finless porpoise (Neophocaena asiaeorientalis asiaeorientalis). (PubMed, Int Microbiol) - "The fecal metabolome underwent significant changes during social separation, with stress-associated metabolites like kainic acid, phenethylamine glucuronide, and paxilline upregulated in the MC group and host health-associated metabolites like butyric acid, 6-hydroxyhexanoic acid, and fosinopril downregulated in the MS group...The study enhances our comprehension of the detrimental effects of social separation, which result in disruptions in the gut microbiome and fecal metabolome. The study is aimed at introducing a new method for assessing the health and welfare of endangered mammals in captivity."

Journal

Clinical Significance and Patterns of Potential Drug-Drug Interactions in Cardiovascular Patients: Focus on Low-Dose Aspirin and Angiotensin-Converting Enzyme Inhibitors. (PubMed, J Clin Med) - "The rates of serious and monitor-closely pDDIs due to 'aspirin + captopril' combinations were significantly higher in P-List than in T-List (p-value < 0.05). Obtained data may suggest better patient adherence to 'aspirin + enalapril' and 'aspirin + lisinopril' combinations, which are potentially superior to the combinations of aspirin with fosinopril, perindopril, and ramipril. An abundance of high-order pDDIs in real-world clinical practice warrants the development of a decision support system aimed at reducing pharmacotherapy-associated risks while integrating patient pharmacokinetic, pharmacodynamic, and pharmacogenetic information."

Journal • Cardiovascular • Infectious Disease • Novel Coronavirus Disease

Modified Fangji Huangqi Decoction alleviates renal interstitial fibrosis by inhibiting TGF-β1/Smad/Snail signaling pathway during epithelial-mesenchymal transition (PubMed, Zhongguo Zhong Yao Za Zhi) - "5-fold and 2-fold concentrations of modified Fangji Huangqi Decoction and fosinopril sodium(positive control) for 7 days...After sh RNA silencing of the Snail gene, the protein and m RNA levels of E-cadherin, α-SMA, and vimentin showed no significant differences before and after treatment with the serum containing the decoction. The results suggest that modified Fangji Huangqi Decoction may alleviate renal interstitial fibrosis by inhibiting the TGF-β1/Smad/Snail signaling pathway and regulating the EMT process."

Journal • Fibrosis • Immunology • CDH1 • TGFB1 • VIM

Drugs for hypertension. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Review • Cardiovascular • Hypertension

Babesia BdFE1 Esterase is Required for the Anti-parasitic Activity of the ACE Inhibitor Fosinopril. (PubMed, J Biol Chem) - "Parasites carrying the L238H mutation in the active site of BdFE1 failed to convert the prodrug to its active moiety and became resistant to the drug. Our data set the stage for the development of this class of drugs for therapy of vector-borne parasitic diseases."

Journal • Cardiovascular • Congestive Heart Failure • Heart Failure • Hypertension

Efficacy of fosinopril and amlodipine in pediatric primary hypertension: a single-center observational study. (PubMed, Front Pediatr) - "Fosinopril may be particularly effective in reducing BP in hypertensive patients of females, central obesity, IR, and hypo-HDL-cholesterolemia. These findings indicate that optimizing antihypertensive medication selection based on the individualized characteristics of children with hypertension may improve the efficacy of antihypertensive treatment."

Journal • Observational data • Cardiovascular • Dyslipidemia • Genetic Disorders • Hypertension • Hypertriglyceridemia • Obesity • Pediatrics

Exploring the disruption of SARS-CoV-2 RBD binding to hACE2. (PubMed, Front Chem) - "We screened ACE inhibitors and previously identified SARS-CoV-2 inhibitors for binding to the RBD-hACE2 interface, and then conducted 500 ns of unrestrained molecular dynamics (MD) simulations of fosinopril, fosinoprilat, lisinopril, emodin, diquafosol, and physcion bound to the interface to assess the binding characteristics of these ligands. However, when lisinopril is bound, it stabilizes the trimeric complex and, therefore, is not an ideal potential drug candidate. Overall, these results reveal important atomistic interactions critical to the binding of the RBD to hACE2 and highlight the significance of including all protein partners in the evaluation of a potential drug candidate."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Equivalent evaluation and biological ingredients of Syringa pinnatifolia against acute myocardial ischemia in mice. (PubMed, J Ethnopharmacol) - "C (40 mg/kg) exerts cardioprotective effect in mice, which was equivalent to that of I and T. Lignans, including both representative compounds (24, 25) and other undescribed molecules with low content, significantly contribute to the anti-AMI effect of SCX. However, the anti-AMI property assessment of SCX should not exclude the contribution from the representative sesquiterpenoid ZER. Hence, the exploration of the final potential substances in SCX requires further investigation."

Journal • Preclinical • Cardiovascular • Congestive Heart Failure • Heart Failure • Myocardial Ischemia • Pain

Angiotensin-converting enzyme inhibitor induced cough compared with placebo, and other antihypertensives: A systematic review, and network meta-analysis. (PubMed, J Clin Hypertens (Greenwich)) - "The order for the rest of the ACEIs are as follows: ramipril (SUCRA 76.4%), fosinopril (SUCRA 72.5%), lisinopril (SUCRA 64.7%), benazepril (SUCRA 58.6%), quinapril (SUCRA 56.5%), perindopril (SUCRA 54.1%), enalapril (SUCRA 49.7%), trandolapril (SUCRA 44.6%) and, captopril (SUCRA 13.7%). All ACEI has the similar risk of developing a cough. ACEI should be avoided in patients who have risk of developing cough, and an ARB or CCB is an alternative based on the patient's comorbidity."

Journal • Retrospective data • Review • Cough • Respiratory Diseases

Association between centrally active angiotensin-converting enzyme inhibitors with dementia risk (AAIC 2023) - "Methods This is a retrospective new-user comparative cohort study using patients ≥50 years old with hypertension who were new users of centrally active ACEIs (captopril, fosinopril, lisinopril, perindopril, ramipril, trandolapril; n = 327,663 or non-centrally active ACEIs (n = 30,867) (benazepril, enalapril, moexipril, quinapril). This work supports causal genetics studies which indicate links between ACE inhibitors in the brain with increased dementia risk. Future work will investigate whether other antihypertensive drug classes differ in risk based on blood brain barrier penetrating ability."

Alzheimer's Disease • Cardiovascular • CNS Disorders • Dementia • Diabetes • Hypertension • Metabolic Disorders • Myocardial Infarction

Chemical composition and cardiotropic activity of Ziziphora clinopodioides subsp. bungeana (Juz.) Rech.f. (PubMed, J Ethnopharmacol) - "Our results support the traditional use of Z. clinopodioides subsp. bungeana for the treatment of coronary diseases. As a result of Z. clinopodioides subsp. bungeana extracts screening in vivo, two extracts were selected as potential cardiotropic agents. Phytochemical analysis of the plant material led to the isolation of five terpenoid derivatives, two megastigmane glycosides, five flavonoids and one cinnamic acid derivative, which could be responsible for the reported biological activity. Future experiments are required to understand the mechanisms of action for the isolated compounds."

Journal • Anesthesia • Cardiovascular • Congestive Heart Failure • Coronary Artery Disease • Heart Failure • Hypertension • Reperfusion Injury

The alkaloids of Corydalis hendersonii Hemsl. contribute to the cardioprotective effect against ischemic injury in mice by attenuating cardiomyocyte apoptosis via p38 MAPK signaling pathway. (PubMed, Chin Med) - "RAF improves cardiac function by inhibiting apoptosis via p38 MAPK signaling pathway, and RAF contributes to the effect against myocardial ischemic injury of TE in mice, which provides a substantial reference for the clinical application against ischemia heart disease and quality control of CH."

IO biomarker • Journal • Preclinical • Cardiovascular • Fibrosis • Heart Failure • Immunology • Inflammation • Myocardial Infarction • Myocardial Ischemia

NT-proBNP Selected Prevention of Cardiac Events in Diabetic Patients (clinicaltrials.gov) - P4 | N=2400 | Recruiting | Sponsor: Martin Huelsmann | Unknown status ➔ Recruiting | Trial completion date: Feb 2021 ➔ Dec 2026 | Trial primary completion date: Feb 2019 ➔ Dec 2025

Enrollment open • Trial completion date • Trial primary completion date • Cardiovascular • Diabetes • Heart Failure • Metabolic Disorders • Type 2 Diabetes Mellitus

"Sie allen haben #schwereSchuld auf sich geladen! Die #Eliten haben wieder #versagt zum #Schaden der #Bevölkerung! #Unverzeihbar! @alena_buyx | @RegSprecherStS | @pfizer_de | @AstraZeneca | @JNJNews | @BioNTech_Group | @bundesrat | @spdbt | @GrueneBundestag | @csu_bt | @fdpbt" (@echtesnordlicht)

Molecular-evaluated and explainable drug repurposing for COVID-19 using ensemble knowledge graph embedding. (PubMed, Sci Rep) - "We show that Fosinopril is a potential ligand for the SARS-CoV-2 nsp13 target. We also provide explanations of our predictions thanks to rules extracted from the KG and instanciated by KG-derived explanatory paths. Molecular evaluation and explanatory paths bring reliability to our results and constitute new complementary and reusable methods for assessing KG-based drug repurposing."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Interventions for preventing and treating kidney disease in IgA vasculitis. (PubMed, Cochrane Database Syst Rev) - "There are no substantial changes in conclusions from this update compared with the initial review or the previous update despite the addition of five studies. From generally low to moderate certainty evidence, we found that there may be little or no benefit in the use of corticosteroids or antiplatelet agents to prevent persistent kidney disease in children with IgAV in participants with no or minimal kidney involvement at presentation. We did not find any studies which evaluated corticosteroids in children presenting with IgAV and nephritic and/or nephrotic syndrome, although corticosteroids are recommended in such children in guidelines. Though heparin may be effective in reducing proteinuria, this potentially dangerous therapy is not justified to prevent serious kidney disease when few children with IgAV develop severe kidney disease. There may be no benefit of cyclophosphamide compared with no specific treatment or corticosteroids. While there may be no benefit in..."

Journal • Review • Acute Kidney Injury • Glomerulonephritis • Immunology • Infectious Disease • Musculoskeletal Pain • Nephrology • Pain • Renal Disease • Rheumatology • Transplantation • Vasculitis

"7/13 Choose meds that are less dialyzable. All ACEi (except fosinopril) are highly dialyzable, whereas all ARBs are non-dialyzable. Many BBs such as metoprolol/atenolol are highly dialyzable while bisoprolol is moderately dialyzable and carvedilol is the least dialyzable." (@Bhanu2405)

"Storstadslivets fördelar – endast för eliten https://t.co/8U3qTCZ7Xe" (@CisionNews)

Chitosan oligosaccharide alleviates renal fibrosis through reducing oxidative stress damage and regulating TGF-β1/Smads pathway. (PubMed, Sci Rep) - "COS has a therapeutic effect on ameliorating renal fibrosis similar to that of the positive control drug fosinopril. Taken together, COS can alleviate renal fibrosis induced by UUO by reducing oxidative stress damage and regulating the TGF-β1/Smad pathway."

Journal • Chronic Kidney Disease • Fibrosis • Immunology • Inflammation • Nephrology • Renal Disease • CDH1 • FN1 • TGFB1

Antihypertensive drug treatment in white-coat hypertension: data from the Plaque HYpertension Lipid-Lowering Italian Study. (PubMed, J Hypertens) - ": In WCH, antihypertensive treatment can effectively and durably reduce office BP. This reduction is accompanied by the inability to lower ambulatory BP from the normal values characterizing this condition at baseline. This appears to be unrelated to the type of treatment employed."

Journal • Cardiovascular • Hypertension